Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
94.65%
-
Total 13F principal
-
$229,815,000
-
Principal change
-
+$2,227,000
-
Total reported market value
-
$217,617,000
-
Number of holders
-
19
-
Value change
-
+$3,131,762
-
Number of buys
-
6
-
Number of sells
-
7
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q4 2020
As of 31 Dec 2020,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
19 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$229,815,000
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, FARALLON CAPITAL MANAGEMENT LLC, BAUPOST GROUP LLC/MA, WOLVERINE ASSET MANAGEMENT LLC, Shaolin Capital Management LLC, Context Capital Management, LLC, TENOR CAPITAL MANAGEMENT Co., L.P., MORGAN STANLEY, ZAZOVE ASSOCIATES LLC, and GABELLI FUNDS LLC.
This page lists
19
institutional bondholders reporting positions
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.